86. Pulmonary arterial hypertension
1,083 clinical trials,   667 drugs   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-000166-37-CZ
(EUCTR)
18/04/201320/11/2012A Phase 2, Multi-Centre, unblinded, parallel dose, safety and effectiveness study of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2United States;France;Serbia;Hungary;Czech Republic;Poland;Australia;Germany;Italy
2EUCTR2012-000153-31-CZ
(EUCTR)
18/04/201320/11/2012A Phase 2, Multi-Center, unblinded study to evaluate the intermediate/long term safety and effectiveness of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals, IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2United States;France;Serbia;Hungary;Czech Republic;Poland;Australia;Germany;Italy
3EUCTR2012-000153-31-PL
(EUCTR)
17/04/201325/01/2013A Phase 2, Multi-Center, unblinded study to evaluate the intermediate/long term safety and effectiveness of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals, IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2France;United States;Serbia;Hungary;Czech Republic;Poland;Australia;Germany;Italy
4EUCTR2012-000166-37-PL
(EUCTR)
17/04/201328/01/2013A Phase 2, Multi-Centre, unblinded, parallel dose, safety and effectiveness study of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2France;United States;Serbia;Hungary;Czech Republic;Poland;Australia;Germany;Italy
5EUCTR2012-000153-31-DE
(EUCTR)
05/03/201329/11/2012A Phase 2, Multi-Center, unblinded study to evaluate the intermediate/long term safety and effectiveness of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals, IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2United States;Serbia;France;Hungary;Czech Republic;Poland;Romania;Australia;Bulgaria;Germany;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2012-000166-37-DE
(EUCTR)
05/03/201329/11/2012A Phase 2, Multi-Centre, unblinded, parallel dose, safety and effectiveness study of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2United States;France;Serbia;Hungary;Czech Republic;Poland;Romania;Australia;Bulgaria;Germany;Italy
7EUCTR2012-000153-31-IT
(EUCTR)
27/02/201313/09/2013A Phase 2, Multi-Center, unblinded study to evaluate the intermediate/long term safety and effectiveness of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension
MedDRA version: 16.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals, IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2France;United States;Serbia;Hungary;Czech Republic;Poland;Australia;Germany;Italy
8EUCTR2012-000166-37-HU
(EUCTR)
22/01/201314/11/2012A Phase 2, Multi-Centre, unblinded, parallel dose, safety and effectiveness study of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2France;United States;Serbia;Czech Republic;Hungary;Poland;Australia;Germany;Italy
9EUCTR2012-000153-31-HU
(EUCTR)
22/01/201314/11/2012A Phase 2, Multi-Center, unblinded study to evaluate the intermediate/long term safety and effectiveness of AIR001 in subjects with high blood pressure in the blood vessels in the lungsA Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: AIR001 Inhalation Solution
Product Code: AIR001
INN or Proposed INN: sodium nitrite
Other descriptive name: SODIUM NITRITE
Aires Pharmaceuticals, IncNULLNot RecruitingFemale: yes
Male: yes
90Phase 2France;United States;Serbia;Czech Republic;Hungary;Poland;Australia;Germany;Italy
10NCT00814645
(ClinicalTrials.gov)
December 200822/12/2008Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy VolunteersA Placebo-Controlled, Phase 1b, Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution (AIR001 INHALATION SOLUTION) in Normal, Healthy VolunteersPulmonary Arterial HypertensionDrug: Sodium Nitrite Inhalation Solution;Drug: Placebo and AIR001 Inhalation Solution (Expansion arm)Aires Pharmaceuticals, Inc.NULLCompleted18 Years55 YearsBoth25Phase 1United States